Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Director Lewis Clayton Jr. Cantley sold 1,000 shares of the firm’s stock in a transaction that occurred on Wednesday, September 13th. The stock was sold at an average price of $65.47, for a total transaction of $65,470.00. Following the completion of the transaction, the director now directly owns 86,394 shares of the company’s stock, valued at $5,656,215.18. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

Lewis Clayton Jr. Cantley also recently made the following trade(s):

  • On Thursday, September 14th, Lewis Clayton Jr. Cantley sold 4,000 shares of Agios Pharmaceuticals stock. The stock was sold at an average price of $65.59, for a total transaction of $262,360.00.
  • On Wednesday, August 23rd, Lewis Clayton Jr. Cantley sold 4,000 shares of Agios Pharmaceuticals stock. The stock was sold at an average price of $56.85, for a total transaction of $227,400.00.
  • On Wednesday, July 19th, Lewis Clayton Jr. Cantley sold 3,500 shares of Agios Pharmaceuticals stock. The stock was sold at an average price of $56.14, for a total transaction of $196,490.00.
  • On Thursday, July 20th, Lewis Clayton Jr. Cantley sold 9,000 shares of Agios Pharmaceuticals stock. The stock was sold at an average price of $56.36, for a total transaction of $507,240.00.

Agios Pharmaceuticals, Inc. (AGIO) traded up 1.28% during mid-day trading on Friday, hitting $66.43. 863,491 shares of the stock were exchanged. Agios Pharmaceuticals, Inc. has a 52 week low of $39.24 and a 52 week high of $67.74. The stock’s market capitalization is $3.21 billion. The company has a 50-day moving average of $59.96 and a 200-day moving average of $54.33.

Agios Pharmaceuticals (NASDAQ:AGIO) last issued its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($1.78) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.57) by ($0.21). Agios Pharmaceuticals had a negative return on equity of 68.15% and a negative net margin of 502.12%. The company had revenue of $11.30 million for the quarter, compared to the consensus estimate of $10.68 million. During the same quarter in the prior year, the company posted ($1.47) EPS. Agios Pharmaceuticals’s revenue was up 62.1% compared to the same quarter last year. On average, equities analysts predict that Agios Pharmaceuticals, Inc. will post ($7.07) EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This piece was first published by American Banking News and is the property of of American Banking News. If you are reading this piece on another domain, it was copied illegally and reposted in violation of United States and international copyright & trademark law. The correct version of this piece can be accessed at https://www.americanbankingnews.com/2017/09/15/lewis-clayton-jr-cantley-sells-1000-shares-of-agios-pharmaceuticals-inc-agio-stock.html.

Several large investors have recently modified their holdings of AGIO. Teachers Advisors LLC boosted its position in shares of Agios Pharmaceuticals by 22.7% during the fourth quarter. Teachers Advisors LLC now owns 29,592 shares of the biopharmaceutical company’s stock worth $1,235,000 after acquiring an additional 5,467 shares during the last quarter. Bank of Montreal Can boosted its position in shares of Agios Pharmaceuticals by 11.7% during the first quarter. Bank of Montreal Can now owns 2,068 shares of the biopharmaceutical company’s stock worth $121,000 after acquiring an additional 216 shares during the last quarter. Nationwide Fund Advisors boosted its position in shares of Agios Pharmaceuticals by 5.2% during the first quarter. Nationwide Fund Advisors now owns 10,104 shares of the biopharmaceutical company’s stock worth $590,000 after acquiring an additional 500 shares during the last quarter. Janney Montgomery Scott LLC bought a new position in shares of Agios Pharmaceuticals during the first quarter worth $257,000. Finally, Russell Investments Group Ltd. boosted its position in shares of Agios Pharmaceuticals by 163.9% during the first quarter. Russell Investments Group Ltd. now owns 2,549 shares of the biopharmaceutical company’s stock worth $149,000 after acquiring an additional 1,583 shares during the last quarter. Hedge funds and other institutional investors own 94.30% of the company’s stock.

AGIO has been the subject of several analyst reports. BidaskClub downgraded shares of Agios Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, August 9th. Oppenheimer Holdings, Inc. set a $75.00 price target on shares of Agios Pharmaceuticals and gave the company a “buy” rating in a report on Thursday, June 1st. Royal Bank Of Canada initiated coverage on shares of Agios Pharmaceuticals in a report on Thursday. They issued an “outperform” rating and a $78.00 price target for the company. Canaccord Genuity set a $90.00 price target on shares of Agios Pharmaceuticals and gave the company a “buy” rating in a report on Tuesday, August 8th. Finally, ValuEngine raised shares of Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, September 1st. Four equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $75.11.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.

Insider Buying and Selling by Quarter for Agios Pharmaceuticals (NASDAQ:AGIO)

Receive News & Ratings for Agios Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.